Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
satoreotide tetraxetan
- Development stage
- Phase 2
- Lead developer
- Ariceum Therapeutics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
Satoreotide tetraxetan is a radiopharmaceutical drug consisting of the somatostatin receptor antagonist peptide satoreotide (JR11) conjugated via the chelator DOTA to the beta-emitting radioisotope lutetium-177. It is designed for targeted radionuclide therapy and imaging (theranostics) in cancers that overexpress somatostatin receptor type 2 (SSTR2), such as neuroendocrine tumors (NETs), small cell lung cancer, and Merkel cell carcinoma. Unlike traditional somatostatin analogues, which are agonists, satoreotide acts as an SSTR2 antagonist, resulting in higher and more stable tumor uptake. Clinical studies have shown promising efficacy and a favorable safety profile in patients with progressive SSTR-positive NETs[1][2][5][6].
- Brand names
- SOMther
- Other names
- lutetium Lu 177 satoreotide tetraxetanLu-177-satoreotide tetraxetanLu177-satoreotide tetraxetanLu 177-satoreotide tetraxetan
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on satoreotide tetraxetan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on satoreotide tetraxetan.